Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib alone or with chemo in older NSCLC patients
NCT00062062Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Oct 2004
- Primary completion
- Aug 2006
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of gefitinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Cancer and Leukemia Group B. Primary endpoint: Progression status at 6 months. Started Oct 2004; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00062062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00062062.